

Seiichiro Mitani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197374/publications.pdf>

Version: 2024-02-01

49
papers

375
citations

933447

10
h-index

839539

18
g-index

49
all docs

49
docs citations

49
times ranked

752
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. <i>Cancers</i> , 2020, 12, 400.	3.7	50
2	Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 5859-5866.	1.1	42
3	Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	32
4	A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. <i>Ecancermedicalsecience</i> , 2018, 12, 847.	1.1	31
5	Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy. <i>Medicine (United Tj ETQq1 1,0,784314,rgBT /O</i>	1.0	29
6	FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis. <i>Anticancer Research</i> , 2017, 37, 7037-7042.	1.1	21
7	Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. <i>Anticancer Research</i> , 2020, 40, 2247-2255.	1.1	16
8	Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. <i>Anti-Cancer Drugs</i> , 2021, 32, 95-101.	1.4	16
9	The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591882029.	3.2	12
10	Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis. <i>Cancer Medicine</i> , 2020, 9, 394-400.	2.8	12
11	Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2018, 10, 863-870.	0.7	11
12	Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy. <i>Case Reports in Oncology</i> , 2016, 9, 106-111.	0.7	10
13	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	3.3	9
14	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1921-1929.	1.3	9
15	Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody. <i>Oncology</i> , 2017, 92, 205-212.	1.9	7
16	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 161, 44-54.	2.8	7
17	A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. <i>Advances in Therapy</i> , 2020, 37, 2853-2864.	2.9	6
18	Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer. <i>BMC Cancer</i> , 2020, 20, 338.	2.6	6

#	ARTICLE	IF	CITATIONS
19	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1197-1203.	2.2	5
20	Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 1159.	2.6	5
21	Safety and tolerability of andeciximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. , 2022, 10, e003518.		5
22	Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502. <i>Journal of Gastroenterology</i> , 2022, , .	5.1	4
23	Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies. <i>Case Reports in Oncology</i> , 2019, 12, 304-310.	0.7	3
24	Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months. <i>Oncology</i> , 2019, 96, 132-139.	1.9	3
25	No benefit from ramucirumab in first-line chemotherapy?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 30-30.	3.0	2
26	Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases. <i>Anticancer Research</i> , 2018, 38, 6501-6506.	1.1	2
27	Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 4050.	2.4	2
28	A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase 1b study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 701-707.	2.2	2
29	Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.. <i>Journal of Clinical Oncology</i> , 2017, 35, 800-800.	1.6	2
30	A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 856-856.	1.6	2
31	Phase 1b study of andeciximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 137-137.	1.6	2
32	Myxoid liposarcoma originating in the retroperitoneum with metastasis to the calcaneus: a rare case report and review of literature. <i>Skeletal Radiology</i> , 2022, 51, 2053-2058.	2.0	2
33	A phase 1b study of andeciximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
34	A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer. <i>Oncologist</i> , 2019, 24, 159-e66.	3.7	1
35	A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 723-723.	1.6	1
36	Peritoneum metastasis (PM) as a prognostic factor in metastatic gastric cancer (MGC) treated with anti-PD-1/PD-L1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3051-3051.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Impact of sarcopenia on survival outcomes in patients (pts) with metastatic gastric cancer (mGC).. Journal of Clinical Oncology, 2017, 35, 141-141.	1.6	1
38	Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status.. Journal of Clinical Oncology, 2017, 35, 744-744.	1.6	1
39	Retrospective observational study of salvage line ramucirumab monotherapy (RAM) for patients (pts) with unresectable advanced gastric cancer (AGC) which was refractory to fluoropyrimidine and taxanes.. Journal of Clinical Oncology, 2018, 36, 129-129.	1.6	1
40	Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: a long-term comparison. Annals of Oncology, 2016, 27, vii75.	1.2	0
41	2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC). Annals of Oncology, 2019, 30, vi100.	1.2	0
42	Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. Oncologist, 2020, 25, e1614-e1620.	3.7	0
43	Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 748-748.	1.6	0
44	Survival outcome of metastatic adenocarcinoma of esophagogastric junction in the trastuzumab era.. Journal of Clinical Oncology, 2016, 34, 117-117.	1.6	0
45	Phase I study of alternate-day administration of S-1, oral leucovorin, and bevacizumab for refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, e14021-e14021.	1.6	0
46	Efficacy of cytotoxic agents after progression of anti-PD-(L)1 antibody for pretreated metastatic gastric cancer.. Journal of Clinical Oncology, 2018, 36, 152-152.	1.6	0
47	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: A multicenter retrospective study.. Journal of Clinical Oncology, 2018, 36, 154-154.	1.6	0
48	A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients.. Journal of Clinical Oncology, 2018, 36, e22128-e22128.	1.6	0
49	Phase Ib study of andecaliximab (GS-5745, ADX) in combination with S-1+platinum chemotherapy in Japanese subjects with advanced gastric or GEJ adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 53-53.	1.6	0